Skip to main content

Advertisement

SpringerLink
Log in

In vitro and in vivo characterization of JNJ-31020028 (N-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a selective brain penetrant small molecule antagonist of the neuropeptide Y Y2 receptor

  • Original Investigation
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Rationale

The lack of potent, selective, brain penetrant Y2 receptor antagonists has hampered in vivo functional studies of this receptor.

Objective

Here, we report the in vitro and in vivo characterization of JNJ-31020028 (N-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a novel Y2 receptor antagonist.

Methods

The affinity of JNJ-31020028 was determined by inhibition of the PYY binding to human Y2 receptors in KAN-Ts cells and rat Y2 receptors in rat hippocampus. The functional activity was determined by inhibition of PYY-stimulated calcium responses in KAN-Ts cells expressing a chimeric G protein Gqi5 and in the rat vas deferens (a prototypical Y2 bioassay). Ex vivo receptor occupancy was revealed by receptor autoradiography. JNJ-31020028 was tested in vivo with microdialysis, in anxiety models, and on corticosterone release.

Results

JNJ-31020028 bound with high affinity (pIC50 = 8.07 ± 0.05, human, and pIC50 = 8.22 ± 0.06, rat) and was >100-fold selective versus human Y1, Y4, and Y5 receptors. JNJ-31020028 was demonstrated to be an antagonist (pKB = 8.04 ± 0.13) in functional assays. JNJ-31020028 occupied Y2 receptor binding sites (~90% at 10 mg/kg) after subcutaneous administration in rats. JNJ-31020028 increased norepinephrine release in the hypothalamus, consistent with the colocalization of norepinephrine and neuropeptide Y. In a variety of anxiety models, JNJ-31020028 was found to be ineffective, although it did block stress-induced elevations in plasma corticosterone, without altering basal levels, and normalized food intake in stressed animals without affecting basal food intake.

Conclusion

These results suggest that Y2 receptors may not be critical for acute behaviors in rodents but may serve modulatory roles that can only be elucidated under specific situational conditions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  • Andres CJ, Antal Zimanyi I, Deshpande MS, Iben LG, Grant-Young K, Mattson GK, Zhai W (2003) Differentially functionalized diamines as novel ligands for the NPY2 receptor. Bioorg Med Chem Lett 13:2883–2885

    Article  CAS  PubMed  Google Scholar 

  • Bacchi F, Mathé AA, Jiménez P, Stasi L, Arban R, Gerrard P, Caberlotto L (2006) Anxiolytic-like effect of the selective neuropeptide Y Y2 receptor antagonist BIIE0246 in the elevated plus-maze. Peptides 27:3202–3207

    Article  CAS  PubMed  Google Scholar 

  • Beck B (2006) Neuropeptide Y in normal eating and in genetic and dietary-induced obesity. Philos Trans R Soc Lond B Biol Sci 361:1159–1185

    Article  CAS  PubMed  Google Scholar 

  • Bonaventure P, Nepomuceno D, Mazur C, Lord B, Rudolph DA, Jablonowski JA, Carruthers NI, Lovenberg TW (2004) Characterization of N-(1-acetyl-2, 3-dihydro-1H-indol-6-yl)-3-(3-cyano-phenyl)-N-[1-(2-cyclopen tyl-ethyl)-piperidin-4yl]acrylamide (JNJ-5207787), a small molecule antagonist of the neuropeptide Y Y2 receptor. J Pharmacol Exp Ther 308:1130–1137

    Article  CAS  PubMed  Google Scholar 

  • Brennauer A, Dove S, Buschauer A (2004) Structure–activity relationships of nonpeptide neuropeptide Y receptor antagonists. Handb Exp Pharmacol 162:505–546

    CAS  Google Scholar 

  • Caberlotto L, Fuxe K, Hurd YL (2000) Characterization of NPY mRNA-expressing cells in the human brain: co-localization with Y2 but not Y1 mRNA in the cerebral cortex, hippocampus, amygdala, and striatum. J Chem Neuroanat 20:327–337

    Article  CAS  PubMed  Google Scholar 

  • Caberlotto L, Arban R, Zambello E (2007) NPY Y2 receptor knock-out mice: influence of genetic background on anxiety related behaviors. Abstract from Society for Neuroscience, Annual Meeting San Diego

  • Carvajal C, Dumont Y, Quirion R (2006) Neuropeptide y: role in emotion and alcohol dependence. CNS Neurol Disord Drug Targets 5:181–195

    Article  CAS  PubMed  Google Scholar 

  • Dautzenberg FM (2005) Stimulation of neuropeptide Y-mediated calcium responses in human SMS-KAN neuroblastoma cells endogenously expressing Y2 receptors by co-expression of chimeric G proteins. Bioch Pharmacol 69:1493–1499

    Article  CAS  Google Scholar 

  • Doods H, Gaida W, Wieland HA, Dollinger H, Schnorrenberg G, Esser F, Engel W, Eberlein W, Rudolf K (1999) BIIE0246: a selective and high affinity neuropeptide Y Y(2) receptor antagonist. Eur J Pharmacol 384:R3–R5

    Article  CAS  PubMed  Google Scholar 

  • Dumont Y, Fournier A, St-Pierre S, Quirion R (1996) Autoradiographic distribution of [125I]Leu31, Pro34]PYY and [125I]PYY3–36 binding sites in the rat brain evaluated with two newly developed Y1 and Y2 receptor radioligands. Synapse 22:139–158

    Article  CAS  PubMed  Google Scholar 

  • Dumont Y, Cadieux A, Doods H, Pheng LH, Abounader R, Hamel E, Jacques D, Regoli D, Quirion R (2000) BIIE0246, a potent and highly selective non-peptide neuropeptide Y Y(2) receptor antagonist. Br J Pharmacol 129:1075–1088

    Article  CAS  PubMed  Google Scholar 

  • Erondu N, Gantz I, Musser B, Suryawanshi S, Mallick M, Addy C, Cote J, Bray G, Fujioka K, Bays H, Hollander P, Sanabria-Bohorquez SM, Eng W, Langstrom B, Hargreaves RJ, Burns HD, Kanatani A, Fukami T, MacNeil DJ, Gottesdiener KM, Amatruda JM, Kaufman KD, Heymsfield SB (2006) Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab 4:275–282

    Article  CAS  PubMed  Google Scholar 

  • Gehlert DR, Gackenheimer SL (1997) Differential distribution of neuropeptide Y Y1 and Y2 receptors in rat and guinea-pig brains. Neuroscience 76:215–224

    Article  CAS  PubMed  Google Scholar 

  • Gehlert DR, Beavers LS, Johnson D, Gackenheimer SL, Schober DA, Gadski RA (1996) Expression cloning of a human brain neuropeptide Y Y2 receptor. Mol Pharmacol 49:224–228

    CAS  PubMed  Google Scholar 

  • Grouzmann E, Buclin T, Martire M, Cannizzaro C, Dorner B, Razaname A, Mutter M (1997) Characterization of a selective antagonist of neuropeptide Y at the Y2 receptor. Synthesis and pharmacological evaluation of a Y2 antagonist. J Biol Chem 272:7699–7706

    Article  CAS  PubMed  Google Scholar 

  • Harro J (2006) CCK and NPY as anti-anxiety treatment targets: promises, pitfalls, and strategies. Amino Acids 31:215–230

    Article  CAS  PubMed  Google Scholar 

  • Heilig M (2004) The NPY system in stress, anxiety and depression. Neuropeptides 38:213–224

    Article  CAS  PubMed  Google Scholar 

  • Herzog H (2002) Hypothalamic Y2 receptors: central coordination of energy homeostasis and bone mass regulation. Drug News Perspect 15:506–510

    Article  CAS  PubMed  Google Scholar 

  • Holets VR, Hokfelt T, Rokaeus A, Terenius L, Goldstein M (1988) Locus coeruleus neurons in the rat containing neuropeptide Y, tyrosine hydroxylase or galanin and their efferent projections to the spinal cord, cerebral cortex and hypothalamus. Neuroscience 24:893–906

    Article  CAS  PubMed  Google Scholar 

  • Kalra SP, Dube MG, Kalra PS (1988) Continuous intraventricular infusion of neuropeptide Y evokes episodic food intake in satiated female rats: effects of adrenalectomy and cholecystokinin. Peptides 9:723–728

    Article  CAS  PubMed  Google Scholar 

  • Kask A, Rägo L, Harro J (1998) Anxiolytic-like effect of neuropeptide Y (NPY) and NPY13–36 microinjected into vicinity of locus coeruleus in rats. Brain Res 788:345–348

    Article  CAS  PubMed  Google Scholar 

  • King PJ, Williams G, Doods H, Widdowson PS (2000) Effect of a selective neuropeptide Y Y(2) receptor antagonist, BIIE0246 on neuropeptide Y release. Eur J Pharmacol 396:R1–R3

    Article  CAS  PubMed  Google Scholar 

  • Kuo LE, Kitlinska JB, Tilan JU, Li L, Baker SB, Johnson MD, Lee EW, Burnett MS, Fricke ST, Kvetnansky R, Herzog H, Zukowska Z (2007) Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat Med 13:803–811

    Article  CAS  PubMed  Google Scholar 

  • Lecci A, Borsini F, Volterra G, Meli A (1990) Pharmacological validation of a novel animal model of anticipatory anxiety in mice. Psychopharmacology (Berl) 101:255–261

    Article  CAS  Google Scholar 

  • Lee EW, Grant DS, Movafagh S, Zukowska Z (2003) Impaired angiogenesis in neuropeptide Y (NPY)-Y2 receptor knockout mice. Peptides 24:99–106

    Article  CAS  PubMed  Google Scholar 

  • MacNeil DJ (2007) NPY Y1 and Y5 receptor selective antagonists as anti-obesity drugs. Curr Top Med Chem 7:1721–1733

    Article  CAS  PubMed  Google Scholar 

  • Martire M, Pistritto G, Mores N, Agnati LF, Fuxe K (1993) Region-specific inhibition of potassium-evoked [3H]noradrenaline release from rat brain synaptosomes by neuropeptide Y-(13–36). Involvement of NPY receptors of the Y2 type. Eur J Pharmacol 230:231–234

    Article  CAS  PubMed  Google Scholar 

  • Mele P, Oberto A, Serra M, Pisu MG, Floris I, Biggio G, Eva C (2004) Increased expression of the gene for the Y1 receptor of neuropeptide Y in the amygdala and paraventricular nucleus of Y1R/LacZ transgenic mice in response to restraint stress. J Neurochem 89:1471–1478

    Article  CAS  PubMed  Google Scholar 

  • Painsipp E, Wultsch T, Edelsbrunner ME, Tasan RO, Singewald N, Herzog H, Holzer P (2008) Reduced anxiety-like and depression-related behavior in neuropeptide Y Y4 receptor knockout mice. Genes Brain Behav 7:532–542

    Article  CAS  PubMed  Google Scholar 

  • Paxinos G, Watson C (1997) The rat brain in stereotaxic coordinates. Academic, San Diego

    Google Scholar 

  • Redrobe JP, Dumont Y, Herzog H, Quirion R (2003) Neuropeptide Y (NPY) Y2 receptors mediate behaviour in two animal models of anxiety: evidence from Y2 receptor knockout mice. Behav Brain Res 141:251–255

    Article  CAS  PubMed  Google Scholar 

  • Redrobe JP, Carvajal C, Kask A, Dumont Y, Quirion R (2004a) Neuropeptide Y and its receptor subtypes in the central nervous system: emphasis on their role in animal models of psychiatric disorders. Handb Exp Pharmacol 162:101–136

    CAS  Google Scholar 

  • Redrobe JP, Dumont Y, Herzog H, Quirion R (2004b) Characterization of neuropeptide Y, Y(2) receptor knockout mice in two animal models of learning and memory processing. J Mol Neurosci 22:159–166

    Article  CAS  PubMed  Google Scholar 

  • Rimondini R, Thorsell A, Heilig M (2005) Suppression of ethanol self-administration by the neuropeptide Y (NPY) Y2 receptor antagonist BIIE0246: evidence for sensitization in rats with a history of dependence. Neurosci Lett 375:129–133

    Article  CAS  PubMed  Google Scholar 

  • Seierstad M, Bonaventure P, Dvorak L, Lord B, Miller KL, Motley ST, Nepomuceno D, Chai W, Dvorak CA, Jablonowski JA, Rudolph DA, Shah CR, Swanson DM, Wong VD, Axe FU, Lovenberg TW, Carruthers NI (2007) Small-molecule Y2 receptor antagonists: identification of a novel and potent series using pharmacophore-based virtual screening. Abstracts of Papers, 234th ACS National Meeting, Boston, MA, USA, August 19–23, 2007

  • Thiele TE, Naveilhan P, Ernfors P (2004) Assessment of ethanol consumption and water drinking by NPY Y2 receptor knockout mice. Peptides 25:975–983

    Article  CAS  PubMed  Google Scholar 

  • Tschenett A, Singewald N, Carli M, Balducci C, Salchner P, Vezzani A, Herzog H, Sperk G (2003) Reduced anxiety and improved stress coping ability in mice lacking NPY-Y2 receptors. Eur J Neurosci 18:143–148

    Article  PubMed  Google Scholar 

  • Zukowska-Grojec Z, Konarska M, McCarty R (1988) Differential plasma catecholamine and neuropeptide Y responses to acute stress in rats. Life Sci 42:1615–1624

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Dr. Kevin Sharp and his staff for technical support. We thank Anita Everson and Kenway Hoey of the Bioanalytical Group and Michele Rizzolio for help in formulating the compound.

Author information

Authors and Affiliations

  1. Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 3210 Merryfield Row, San Diego, CA, 92121, USA

    James R. Shoblock, Natalie Welty, Diane Nepomuceno, Brian Lord, Leah Aluisio, Ian Fraser, S. Timothy Motley, Steve W. Sutton, Kirsten Morton, Ruggero Galici, John R. Atack, Lisa Dvorak, Devin M. Swanson, Nicholas I. Carruthers, Curt Dvorak, Timothy W. Lovenberg & Pascal Bonaventure

Authors
  1. James R. Shoblock
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Natalie Welty
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Diane Nepomuceno
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Brian Lord
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Leah Aluisio
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ian Fraser
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S. Timothy Motley
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Steve W. Sutton
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Kirsten Morton
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ruggero Galici
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. John R. Atack
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Lisa Dvorak
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Devin M. Swanson
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Nicholas I. Carruthers
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Curt Dvorak
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Timothy W. Lovenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Pascal Bonaventure
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James R. Shoblock.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shoblock, J.R., Welty, N., Nepomuceno, D. et al. In vitro and in vivo characterization of JNJ-31020028 (N-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a selective brain penetrant small molecule antagonist of the neuropeptide Y Y2 receptor. Psychopharmacology 208, 265–277 (2010). https://doi.org/10.1007/s00213-009-1726-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-009-1726-x

Keywords

Search

Navigation